Transaction · 0001437749-25-002424

Stengone Carmine N.

Stengone Carmine N., CEO, PRES, reported a transaction classified as grant at Contineum Therapeutics, Inc. involving 300000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 300000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO, PRES
CTNMContineum Therapeutics, Inc.
Filing timeJan 31
Trade dateJan 31, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

CTNM price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CTNM since 2025-01-31Filed 586 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001437749-25-002424
Stock Option (right to buy)
Transaction date
Jan 31, 2025
Filed Jan 31, 2025, 09:35 PM · 0d delay
Shares
300k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
300k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO and President

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafte…

Original filing · 0001437749-25-002424
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CTNM